Christopher Brown, MD
Cardiovascular Disease · Mobile, ALNPI 1982685640
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $371 of the $446 with a category attached, or 83.1%. Biotronik Inc. accounts for 74.3% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2021 at $225 and has fallen 66.0% since, to $77 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in AL, where the typical reported total is $2,733.
Across 16 payments — averaging $27.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotronik Inc.$332
- Abiomed$58
- Abbott$25
- GSK$18
- Boehringer Ingelheim$13
Across 318 payments — averaging $4385.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$715K
- AstraZeneca$174K
- Eli Lilly$159K
- Novartis$156K
- Boehringer Ingelheim International GmbH$46K
- Bayer$43K
- plus $102K from 5 others
What the payments were for
- Food & beverage$37183%
- Education$7517%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotronik Inc. | 11 | $332 |
| Abiomed | 2 | $58 |
| Abbott | 1 | $25 |
| GSK | 1 | $18 |
| Boehringer Ingelheim | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Solia$137
- BioMonitor$137
- Rivacor$137
- Edora$137
- Acticor$137
How this compares
$446 in reported general payments places this provider in the 20th percentile of 292 cardiovascular disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 625 | $602,762 |
| XareltoRivaroxaban | 230 | $226,480 |
| EntrestoSacubitril/Valsartan | 100 | $97,902 |
| Ranolazine ErRanolazine | 153 | $20,201 |
| Metoprolol Succinate | 977 | $13,955 |
| BrilintaTicagrelor | 17 | $12,871 |
| FarxigaDapagliflozin Propanediol | 18 | $9,243 |
| Atorvastatin Calcium | 572 | $8,591 |
| Amiodarone Hcl | 345 | $8,542 |
| Rosuvastatin Calcium | 436 | $5,572 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 160 | $5,165 |
| Midodrine Hcl | 26 | $5,149 |
| Flecainide Acetate | 70 | $4,532 |
| Potassium Chloride | 227 | $4,327 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 16 | $4,292 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Mobile
- Dennis ThomasMobile$894K
- Michael RihnerMobile$13K
- Ghulam AwanMobile$9K
- David FienoAlabaster$421K
- Vikram AroraBirmingham$271K
- Jason ThompsonBirmingham$248K
- Michael WilenskyBirmingham$241K
- Mustafa AhmedBirmingham$218K
- Frederick GaskinBirmingham$115K
- Pankaj AroraBirmingham$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.